Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in moderate to severe plaque psoriasis
NCT02129777Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of namilumab in plaque psoriasis (5 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants Achieving 75 Percent Reduction From Baseline Psoriasis Area and Severity Index (PASI) Score at 12 weeks. Started Jun 2014; status: completed.
02
Drugs
namilumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02129777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129777.